Comorbidity and Disease Activity in Multiple Sclerosis is a research paper published in JAMA Neurology (2024). On theSindex it has a DataRank of 0.574. It has been cited 45 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.574
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Canadian Institutes of Health Research
Grant: unidentified
unidentified
National Institutes of Health
Grant: 1R21NS041986-01
Combination Therapy in Multiple Sclerosis
National Institutes of Health
Grant: 5U01NS045719-04
Combination Therapy in Multiple Sclerosis
Fields of Study
Keywords
Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple Sclerosis
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis